Compare PAGSEG Inc (PAGS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? PAGSEG Inc trades at $10.79 (market cap $2.99B), while Travere Therapeutics Inc. Common Stock trades at $54.68 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is the larger of the two by market cap, and PAGSEG Inc pays a 10.34% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PAGSEG Inc for 27 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PAGS | TVTX | |
|---|---|---|
Market Cap | $2.99B | $5.02B |
Volume | 3,873,797 | 2,060,842 |
Sector | Industrials | Health |
52-Week High | $12.00 | $67.52 |
52-Week Low | $8.44 | $26.79 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $11.05B | $5.15B |
Dividend Yield | 10.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $10.99, down 1.35% today, with strong bullish technical signals from moving averages. The stock shows attractive valuation metrics with P/E of 7.2 and P/S of 0.75, supported by solid profitability including 10.45% net margin and 14.54% ROE. Recent Q2 2026 earnings beat expectations at $0.41 per share versus $0.389 expected, though Q1 2026 missed estimates.
The outlook remains positive with analyst consensus favoring Buy ratings (62.5%) and a $10.70 price target. Key risks include Brazilian macroeconomic sensitivity and competitive pressures in digital banking. The upcoming dividend payment of $0.28 in September 2026 provides additional shareholder return potential.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
